Get in on Sana Biotechnology Inc.’s (SANA) buy-in window today! – SETE News

Sana Biotechnology Inc. (NASDAQ: SANA) stock fell -1.04% on Friday to $6.64 against a previous-day closing price of $6.71. With 1.49 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.45 million shares. The 52-week range on SANA shows that it touched its highest point at $26.60 and its lowest point at $3.92 during that stretch. It currently has a 1-year price target of $13.33.

Lithium Stocks In The Spotlight

Here's a company undiscovered by Wall Street and trading below $0.30 per share which just recently uncovered 8 high-quality targets on unexplored ground, and drills will be turning later this year. Very few investors know about it yet so the ground-floor opportunity below $0.30 won't be around much longer. It's a brand new breed of lithium explorer all you need to do is click and the name and trading symbol is yours.

It's all in the FREE report you can get here..

Sponsored

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SANA was down-trending over the past week, with a drop of -3.21%, but this was down by -21.33% over a month. Three-month performance surged to 61.17% while six-month performance rose 15.68%. The stock lost -73.04% in the past year, while it has lost -57.11% so far this year. A look at the trailing 12-month EPS for SANA yields -1.61 with Next year EPS estimates of -2.37. For the next quarter, that number is -0.53. This implies an EPS growth rate of -37.80% for this year and -12.40% for next year.

At present, 187.63 million SANA shares are outstanding with a float of 168.88 million shares on hand for trading. On Jul 14, 2022, short shares totaled 22.35 million, which was 11.78% higher than short shares on Jun 14, 2022. In addition to Dr. Steven D. Harr M.D. as the firms Pres, CEO & Director, Dr. Richard C. Mulligan Ph.D. serves as its Exec. Vice Chairman & Head of SanaX.

Through their ownership of 85.43% of SANAs outstanding shares, institutional investors have majority control over the company. Other institutions hold 32.91% of SANA, in contrast to 27.48% held by mutual funds. Shares owned by individuals account for 14.37%. As the largest shareholder in SANA with 5.79% of the stake, Baillie Gifford & Co. holds 11,011,462 shares worth 11,011,462. A second-largest stockholder of SANA, Canada Pension Plan Investment Bo, holds 10,175,000 shares, controlling over 5.35% of the firms shares. SSgA Funds Management, Inc. is the third largest shareholder in SANA, holding 8,594,413 shares or 4.52% stake. With a 5.35% stake in SANA, the Canada Pension Plan is the largest stakeholder. A total of 10,175,000 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 3.60% of SANA stock, is the second-largest Mutual Fund holder. It holds 6,854,877 shares valued at 46.68 million. Scottish Mortgage Investment Trus holds 2.94% of the stake in SANA, owning 5,586,264 shares worth 38.04 million.

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SANA since 4 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that its UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SANA analysts setting a high price target of $18.00 and a low target of $7.00, the average target price over the next 12 months is $12.75. Based on these targets, SANA could surge 171.08% to reach the target high and rise by 5.42% to reach the target low. Reaching the average price target will result in a growth of 92.02% from current levels.

It is also common to use earnings estimates to evaluate a firms growth potential and to determine trading strategy. SANA will report FY 2022 earnings on 03/22/2023. Analysts have provided yearly estimates in a range of -$1.64 being high and -$2.30 being low. For SANA, this leads to a yearly average estimate of -$1.94. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Sana Biotechnology Inc. surprised analysts by $0.04 when it reported -$0.47 EPS against a consensus estimate of -$0.51. The surprise factor in the prior quarter was $0.30. Based on analyst estimates, the high estimate for the next quarter is -$0.39 and the low estimate is -$0.53. The average estimate for the next quarter is thus -$0.48.

Insiders traded SANA stock several times over the past three months with 2 Buys and 0 Sells. In these transactions, 3,594 shares were bought while 0 shares were sold. The number of buy transactions has increased to 8 while that of sell transactions has risen to 3 over the past year. The total number of shares bought during that period was 103,683 while 60,333 shares were sold.

See the original post:
Get in on Sana Biotechnology Inc.'s (SANA) buy-in window today! - SETE News